Europeiska unionen - tyska - EMA (European Medicines Agency)

eisai gmbh - rufinamide - epilepsie - antiepileptika, - inovelon ist angezeigt als zusatztherapie in der behandlung von epileptischen anfällen verbunden mit lennox-gastaut-syndrom bei patienten 4 jahren und älter.

Europeiska unionen - tyska - EMA (European Medicines Agency)

bial - portela & ca, s.a. - eslicarbazepinacetat - epilepsie - antiepileptika, - zebinix ist als adjunktive therapie bei erwachsenen, jugendlichen und kindern ab 6 jahren mit fokalen anfällen mit oder ohne sekundäre generalisierung indiziert.

Schweiz - tyska - Swissmedic (Swiss Agency for Therapeutic Products)

ingenus pharmaceuticals gmbh - etoposidum - konzentrat zur herstellung einer infusionslösung - etoposidum 100 mg, acid citricum, polysorbatum 80, macrogolum 300, conserv.: alcohol benzylicus 150 mg, ethanolum 1,2 g, excipiens ad-lösung für 5 ml. - zytostatika - synthetika

Schweiz - tyska - Swissmedic (Swiss Agency for Therapeutic Products)

ingenus pharmaceuticals gmbh - etoposidum - konzentrat zur herstellung einer infusionslösung - etoposidum 500 mg, acid citricum, polysorbatum 80, macrogolum 300, conserv.: alcohol benzylicus 750 mg, ethanolum 6 g, excipiens ad-lösung für 25 ml. - zytostatika - synthetika

Schweiz - tyska - Swissmedic (Swiss Agency for Therapeutic Products)

ingenus pharmaceuticals gmbh - etoposidum - konzentrat zur herstellung einer infusionslösung - etoposidum 1 g, acid citricum, polysorbatum 80, macrogolum 300, conserv.: alcohol benzylicus 1,5 g, ethanolum 12 g, excipiens ad-lösung für 50 ml. - zytostatika - synthetika

Europeiska unionen - tyska - EMA (European Medicines Agency)

accord healthcare s.l.u. - lacosamid - epilepsie - antiepileptika, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Europeiska unionen - tyska - EMA (European Medicines Agency)

angelini pharma s.p.a - cenobamate - epilepsie - antiepileptika, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Europeiska unionen - tyska - EMA (European Medicines Agency)

extrovis eu ltd. - lacosamid - epilepsie - antiepileptika, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Österrike - tyska - AGES (Agentur für Gesundheit und Ernährungssicherheit)

agepha pharma sro - prednisolon - glucocorticoids

Österrike - tyska - AGES (Agentur für Gesundheit und Ernährungssicherheit)

alfasigma s.p.a. - betamethason dinatriumphosphat - glucocorticoids